Evidence map›Paper›PMID 31996370›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2020

Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.

Rebecca Landy, Lauren C Houghton, Christine D Berg, Robert L Grubb, Hormuzd A Katki, Amanda Black

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rebecca LandyDivision of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland. rebecca.landy@nih.gov blacka@mail.nih.gov.
Lauren C HoughtonMailman School of Public Health, Columbia University, New York, New York.
Christine D BergDivision of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Robert L GrubbDepartment of Urology, Medical University of South Carolina, Charleston, South Carolina.
Hormuzd A Katki *Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.ORCID 0000-0003-2002-0095
Amanda Black *Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland. rebecca.landy@nih.gov blacka@mail.nih.gov.
Cancer Genetics (United States) · USColumbia University · USMedical University of South Carolina · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Longer-than-annual screening intervals have been suggested to improve the balance of benefits and harms in prostate cancer screening. Many researchers, societies, and guideline committees have suggested that screening intervals could depend on the prostate-specific antigen (PSA) result. We analyzed data from men (

Indexed as

AgedBiomarkers, TumorCase-Control StudiesEarly Detection of CancerEthnicityFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesProstate-Specific AntigenProstatic NeoplasmsSurvival RateBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID31996370
PMCPMC7339970
OpenAlexW3003550774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.